GleamWall
中文EN

ATXI AVENUE THERAPEUTICS, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1644963 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY25.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-160.0%
ROA-106.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets104.9%
Debt / equity—
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-22.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0—$0$0$1.40M—$0
R&D expense$212,000$247,000$200,000$257,000$177,000$192,000$411,000$565,000
SG&A expense$492,000$460,000$514,000$698,000$547,000$915,000$1.49M$1.03M
Operating income-$704,000-$707,000-$714,000-$752,000-$724,000$297,000-$1.91M-$1.60M
Net income-$691,000-$690,000-$695,000-$709,000-$683,000$335,000-$1.85M-$1.54M
EPS (basic)-0.20-0.21-0.21—-0.210.11-0.62—
EPS (diluted)————————
Balance sheet
Cash & equivalents$1.52M$1.94M$2.42M$2.85M$3.71M$3.33M$3.50M$2.59M
Total assets$1.53M$1.98M$2.47M$2.93M$3.73M$4.16M$3.59M$2.67M
Current liabilities$1.60M$1.41M$1.27M$1.10M$1.42M$1.33M$1.26M$816,000
Total liabilities$1.60M$1.41M$1.27M$1.10M$1.42M$1.33M$1.26M$816,000
Shareholders' equity-$75,000$569,000$1.20M$1.83M$3.56M$4.06M$3.51M$2.80M
Shares outstanding3.29M3.29M3.29M3.18M3.18M3.18M3.18M2.11M
Cash flow statement
Operating cash flow-$422,000-$475,000-$438,000-$854,000$383,000-$176,000-$1.19M-$764,000
Investing cash flow———————$0
Financing cash flow$0$0$0$0$0$0$2.09M$761,000
Stock-based compensation$47,000$61,000$61,000$142,000$163,000$175,000$185,000$522,000

Free plan shows the latest 8 periods; Pro shows all 43 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.